The tale of dabigatran sounds some cautionary notes about proper critical appraisal of new randomised controlled trials,care in deciding on the generalisability of results, judicious screening of patients and lessons about the politics around increasingly lucrative drugs. The old lesson of caveat utilitor still holds: let the user beware!
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5694/mja12.10729 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!